[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350324-105":59,"doc-detail-350324-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunological-consequences-of-chemotherapy-implications-for-cancer-immunotherapy","Immunological consequences of chemotherapy - implications for cancer immunotherapy","","Despite the success of immunotherapy, chemotherapy remains central to first-line cancer treatment, while many immunotherapy modalities were historically used in later lines. Growing clinical evidence shows better outcomes when immunotherapy is given to less-pretreated patients, yet the mechanisms behind this benefit are incomplete. Systemic chemotherapy can transiently remodel the tumor immune microenvironment to enhance antitumor immunity, but it can also cause durable immune-cell damage that increases risk of secondary malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunological-consequences-of-chemotherapy-implications-for-cancer-immunotherapy/350324/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunological-consequences-of-chemotherapy-implications-for-cancer-immunotherapy/350324.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is chemotherapy still used for most cancer patients despite advances in immunotherapy?","Question",{"text":112,"@type":113},"Chemotherapy remains the backbone of front-line therapy for most patients, even though immunotherapies have become important cancer treatments.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can chemotherapy improve immunotherapy responses when given earlier in treatment?",{"text":117,"@type":113},"Accumulating evidence shows improved clinical responses when immunotherapy is administered to less heavily pretreated patients, likely linked to chemotherapy-driven changes in the tumor immune microenvironment and immune cell dynamics.",{"name":119,"@type":110,"acceptedAnswer":120},"What long-term effects of chemotherapy on the immune system are highlighted in the review?",{"text":121,"@type":113},"The review describes lasting deleterious effects on immune cells, including clonal hematopoiesis, cellular aging and senescence, persistence for years after exposure, and increased susceptibility to secondary malignancies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350324,1791272985,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Open access Review  \n Immunological consequences of  \nchemotherapy: implications for cancer immunotherapy  \nGina G Bishara,1,2 Katharine Umphred-Wilson,1 Scott I Abrams  ,1 Joyce E Ohm  ,2 Scott H Olejniczak  1  \nTo cite: Bishara GG, UmphredWilson K, Abrams SI, et al. Immunological consequences of chemotherapy: implications for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 2026;14:e014099 . doi:10 . 1136/ jitc-2025-014099  \nGGB and KU-W contributed equally.  \nAccepted 07 May 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA 2Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA  \nCorrespondence to  \nDr Scott H Olejniczak;  \nscott.olejniczak@roswellpark. org  \nABSTRACT  \nDespite the success of immunotherapy, chemotherapy remains the backbone of front-line therapy for most patients with cancer. Immune checkpoint inhibitors, T cell engagers, and adoptive cell therapies have traditionally been relegated to second-line or later settings. However, accumulating evidence of improved clinical responses when immunotherapy is administered to less heavily pretreated patients has prompted the incorporation of these modalities earlier in treatment scheduling. Yet, mechanistic understanding of factors driving improved immunotherapy response rates among less heavily pretreated patients remains limited. Decades of study have established that systemic chemotherapy produces immunomodulatory effects, fundamentally altering the immune landscape. Chemotherapy transiently modulates the tumor immune microenvironment to support antitumor immune responses through several mechanisms, including depletion of immunosuppressive cells and induction of immunogenic cell death. However, chemotherapy exposure is also associated with lasting deleterious effects on cells of the immune system, promoting clonal hematopoiesis, cellular aging, and senescence through a variety of molecular mechanisms. Importantly, lasting chemotherapy-induced changes can persist in immune cells of patients with cancer and survivors for several years following chemotherapy exposure, making them susceptible to secondary malignancies. Evidence of lasting damage to the immune system raises important questions regarding how prior chemotherapy exposure ultimately influences the efficacy of immunotherapy. In this review, we provide an overview of the consequences of chemotherapy on the cells of the immune system, with particular focus on the long-term deleterious effects of chemotherapy exposure, translational implications for modern immunotherapy, and potential strategies to overcome or circumvent chemotherapy-induced cellular damage.  \nINTRODUCTION  \nSince its advent in the early 1900s, chemotherapy has remained the most widely used therapeutic approach for cancer treatment.1 Common classes of chemotherapy include antimetabolites, alkylating agents, platinumbased compounds, microtubule inhibitors, and anthracyclines, each acting through  \ndistinct mechanisms.2 Over the past decade anda half, immunotherapies have emerged as potent cancer therapies capable of engaging the immune system and generating durable antitumor responses.3 The 2011 approval ofipilimumab, an immune checkpoint inhibitor (ICI) that blocks the inhibitory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, for use in melanoma ushered in a new era of harnessing the immune system to treat patients with cancer.4 In 2017, treatment options for B cell malignancies were expanded with the approval of the first CD19-targeting chimeric antigen receptor (CAR) T cell, an adoptive cell therapy (ACT) that uses genetically modified T cells to target a tumor antigen.5 Additional standard-of-care immunotherapies for cancer include monoclonal antibodies, cancer vaccines, tumor-infiltrating ly","cbCaijr2GcobTqG8","https://ap.wps.com/l/cbCaijr2GcobTqG8","pdf",4450533,14,"English","# Abstract\n# Introduction\n## Mechanistic background: chemotherapy and immunotherapy scheduling\n## Short-term immunomodulatory effects and variable response outcomes\n## Long-term immune-cell damage and implications for efficacy\n# Transient effects of chemotherapy on the tumor immune microenvironment","[{\"question\":\"Why is chemotherapy still used for most cancer patients despite advances in immunotherapy?\",\"answer\":\"Chemotherapy remains the backbone of front-line therapy for most patients, even though immunotherapies have become important cancer treatments.\"},{\"question\":\"How can chemotherapy improve immunotherapy responses when given earlier in treatment?\",\"answer\":\"Accumulating evidence shows improved clinical responses when immunotherapy is administered to less heavily pretreated patients, likely linked to chemotherapy-driven changes in the tumor immune microenvironment and immune cell dynamics.\"},{\"question\":\"What long-term effects of chemotherapy on the immune system are highlighted in the review?\",\"answer\":\"The review describes lasting deleterious effects on immune cells, including clonal hematopoiesis, cellular aging and senescence, persistence for years after exposure, and increased susceptibility to secondary malignancies.\"}]","Immunological consequences of chemotherapy - implications for cancer immunotherapy | PDF",1790088458,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd07379f1e2041c07f3e115c6778cb37.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de11557e68f493cb06dc228a8604afe7.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/730d36a18a114e68557dc86f82cf0319.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfe8253554efe82ea61169e29109165b.webp",980,1306]